← Research index · Disorder page · Source YAML

Cross-provider research synthesis

Liver Cirrhosis

MONDO:0005155 Curated 2026-07-04T00:00:00Z 9 harmonized findings

falcon · 22 citations asta · 20 citations

Concordant asserts the finding Partial supports a weaker/qualified form Contradictory conflicts with it Silent does not address it

Harmonized findings

Activated hepatic stellate cells (HSCs) are the central effector of hepatic fibrogenesis in cirrhosis, transdifferentiating into ECM-producing myofibroblasts (fibrillar collagen, alpha-SMA) after chronic liver injury.

UNANIMOUS INTEGRATED

pathophysiology

Provider	Stance	Score	Evidence
falcon	CONCORDANT	95%	Hepatic stellate cells (HSCs) are the dominant source of myofibroblasts and fibrillar collagens (type I predominates) once activated by injury cues Falcon names HSCs as the dominant myofibroblast/collagen source upon activation, the core fibrogenic mechanism. DOI:10.3390/ijms25147873
asta	CONCORDANT	90%	Activated hepatic stellate cells (HSCs) are well believed to be the key effectors of liver fibrogenesis by producing matrix proteins during chronic liver injury. Asta retrieves the same claim from a primary HSC-mechanism paper, calling HSCs the key effectors of fibrogenesis. PMID:38725842

TGF-beta and PDGF signaling are the principal profibrotic pathways driving HSC activation, collagen synthesis, and ECM accumulation.

UNANIMOUS INTEGRATED

pathophysiologygene_function

Provider	Stance	Score	Evidence
falcon	CONCORDANT	95%	TGF-β/Smad is a master profibrotic driver increasing collagen (COL1A1/1A2) and TIMPs while reducing MMP activity Falcon details TGF-beta/Smad as the master profibrotic axis and elsewhere names PDGF as the HSC mitogen. DOI:10.3390/ph17121724
asta	CONCORDANT	90%	signaling pathways involving transforming growth factor-beta (TGF-β) and platelet-derived growth factor (PDGF) are critical for the activation of hepatic stellate cells, which are pivotal in fibrosis development Asta retrieves the same TGF-beta/PDGF-to-HSC-activation statement verbatim from a 2024 review. PMID:39770566

Sinusoidal/endothelial remodeling (LSEC capillarization, loss of fenestrae, increased intrahepatic vascular resistance) drives portal hypertension, the principal complication of cirrhosis.

UNANIMOUS INTEGRATED

pathophysiologyphenotype

Provider	Stance	Score	Evidence
falcon	CONCORDANT	90%	LSEC capillarization with collagen IV basement membrane and loss of fenestrae increases sinusoidal resistance and portal pressure Falcon gives the LSEC-capillarization mechanism for increased intrahepatic resistance and portal pressure. DOI:10.3390/biomedicines12102229
asta	CONCORDANT	85%	Portal hypertension (PH) is the most common and dreadful complication of CLD, and it occurs when the hepatic venous pressure gradient (HVPG) increases above 10 mmHg. Asta frames portal hypertension as the most common complication and, in the same LSEC-focused paper, ties it to sinusoidal dysfunction. PMID:28239607

Cirrhosis is the shared end stage of diverse chronic liver injuries — viral hepatitis (HBV/HCV), alcohol, metabolic/NASH, autoimmune, cholestatic, and genetic disease.

MAJORITY INTEGRATED

epidemiologypathophysiology

Provider	Stance	Score	Evidence
asta	CONCORDANT	90%	Cirrhosis develops from chronic hepatitis, that can be caused by hepatitis B virus (HBV), hepatitis C virus (HCV), alcoholic liver disease (ALD), non-alcoholic steatohepatitis (NASH), autoimmune hepatitis, and genetic diseases, including hemochromatosis and Wilson's disease Asta enumerates the full etiologic spectrum, including specific genetic causes (hemochromatosis, Wilson disease). PMID:33317250
falcon	PARTIAL	60%	chronic injury (viral, metabolic, alcohol, cholestasis, toxins) triggers hepatocyte damage Falcon lists the etiologic categories generically as injury initiators but does not enumerate individual named etiologies the way Asta does.

No antifibrotic drug is approved to treat established cirrhosis; removing or treating the underlying cause remains the only proven disease-modifying strategy.

UNANIMOUS INTEGRATED

treatment

Provider	Stance	Score	Evidence
falcon	CONCORDANT	90%	Disease modification by removing injury (e.g., antivirals for viral hepatitis, alcohol abstinence, MASLD weight loss) is associated with fibrosis stabilization/regression, especially in early stages Falcon frames etiology-directed therapy as the disease-modifying approach and notes no antifibrotic is yet approved for cirrhosis. DOI:10.3390/biomedicines12102229
asta	CONCORDANT	90%	addressing the underlying cause remains the only proven strategy to halt or reverse liver fibrosis progression Asta retrieves the explicit statement that addressing the underlying cause is the only proven strategy, effective antifibrotics remaining a challenge. PMID:40283943

Liver fibrosis (and early cirrhosis) is a dynamic, potentially reversible process; regression follows removal of the injurious stimulus, aided by macrophage-mediated matrix degradation.

UNANIMOUS LEAD

prognosispathophysiology

Provider	Stance	Score	Evidence
falcon	CONCORDANT	85%	macrophage subsets promote matrix degradation (e.g., MMP9/12) and HSC inactivation, enabling partial reversal Falcon gives a mechanistic account of regression (macrophage MMP-driven matrix degradation and HSC inactivation). DOI:10.3390/ijms25147873
asta	CONCORDANT	80%	liver fibrosis is recognized to be regressive, as observed clinically in patients with hepatitis B infection or alcohol-related liver disease Asta retrieves the clinical observation that fibrosis is regressive after etiologic treatment, matching Falcon's reversibility claim. PMID:38725842

Cirrhosis is a premalignant state that predisposes to hepatocellular carcinoma across all etiologies.

SINGLE LEAD

comorbidityprognosis

Provider	Stance	Score	Evidence
asta	CONCORDANT	90%	All patients with cirrhosis are in a premalignant condition and predispose to hepatocellular carcinoma (HCC), irrespective of etiology Asta retrieves an explicit statement that cirrhosis is premalignant and predisposes to HCC regardless of cause. DOI:10.21203/rs.3.rs-1266028/v1
falcon	SILENT	—	Falcon's pathophysiology-focused report does not address hepatocellular carcinoma or the cirrhosis-to-cancer progression.

Common human genetic risk/protective variants (PNPLA3 I148M, TM6SF2 E167K, MBOAT7, GCKR, HSD17B13) modulate fibrosis/cirrhosis trajectory in metabolic liver disease.

SINGLE LEAD

genetic_factor

Provider	Stance	Score	Evidence
falcon	CONCORDANT	85%	PNPLA3 (I148M risk), TM6SF2 (E167K risk), MBOAT7 (rs641738 risk), GCKR (risk), and HSD17B13 (loss-of-function protective) Falcon specifies the canonical common-variant genetic architecture of metabolic cirrhosis risk, including the protective HSD17B13 allele. DOI:10.33696/gastroenterology.5.054
asta	SILENT	—	Asta's retrieved papers cover Mendelian genetic causes (hemochromatosis, Wilson disease) but do not surface the common risk/protective variant panel.

Oxidative stress / reactive oxygen species are a key driver of HSC activation and liver fibrosis progression.

MAJORITY LEAD

pathophysiology

Provider	Stance	Score	Evidence
asta	CONCORDANT	80%	release of reactive oxygen species (ROS) and other fibrogenic/ proinflammatory mediators Asta surfaces multiple papers placing ROS/oxidative stress centrally in HSC activation and fibrosis progression. PMID:38725842
falcon	PARTIAL	45%	once activated by injury cues (e.g., TGF-β, PDGF, inflammatory cytokines, oxidative stress) Falcon lists oxidative stress among HSC-activating injury cues but does not develop ROS as a central, standalone fibrogenic driver.

Narrative

Overview

Both providers frame liver cirrhosis as the shared end stage of chronic liver injury, converging on a hepatic stellate cell (HSC)-centered fibrogenesis model. Falcon (Edison Scientific) delivers a synthesized, mechanism-forward pathophysiology narrative — HSC activation, LSEC capillarization, portal hemodynamics, immune-stromal crosstalk, and genetic modifiers of metabolic liver disease. Asta is retrieval-only, returning ranked snippets from twenty papers rather than a synthesis, so its "framing" is emergent from the corpus: strong on named etiologies, oxidative stress, the cirrhosis-to-HCC axis, and the recurring message that no antifibrotic drug is yet approved.

Agreement

The two reports agree on the core mechanistic spine of the disease: activated HSCs transdifferentiating into ECM-producing myofibroblasts are the central effector of fibrogenesis; TGF-beta and PDGF are the principal profibrotic signals driving that activation; sinusoidal/endothelial remodeling raises intrahepatic vascular resistance and produces portal hypertension as the dominant complication; fibrosis (and early cirrhosis) is dynamic and potentially reversible once the injurious stimulus is removed; and there is no approved antifibrotic therapy for established cirrhosis, leaving etiology-directed treatment as the only proven disease-modifying strategy.

Divergence

Divergence is coverage-driven, not conflicting — no direct contradictions were found. Falcon uniquely supplies the common human genetic risk/protective variant architecture of metabolic cirrhosis (PNPLA3 I148M, TM6SF2 E167K, MBOAT7, GCKR, protective HSD17B13) and the fine-grained LSEC/nitric-oxide microvascular mechanism. Asta uniquely surfaces the fully enumerated etiologic spectrum (HBV, HCV, alcohol, NASH, autoimmune, hemochromatosis, Wilson disease), the explicit premalignant cirrhosis-to-hepatocellular-carcinoma progression across all etiologies, and a heavier oxidative-stress/ROS emphasis that Falcon mentions only as one of several HSC-activating injury cues.

Integration

The strongly concordant, mechanistically central findings should be promoted into the disorder YAML: HSC-driven fibrogenesis, the TGF-beta/PDGF profibrotic axis, LSEC capillarization driving portal hypertension, the etiologic spectrum, and the treatment reality that only etiology-directed therapy is proven disease-modifying. These are dual-provider supported and align with the existing cirrhosis pathophysiology model (fibrotic_response conformance).

Not integrated (leads)

Several claims are retained as leads pending single-source confirmation or dedicated evidence verification: fibrosis reversibility (concordant but prognostically nuanced), the cirrhosis-to-HCC premalignant progression (Asta-only, better suited to a comorbidity/trajectory entry), the common genetic risk/protective variant panel (Falcon-only, needs per-variant PMID verification before genetic-factor curation), and the oxidative-stress/ROS driver (Asta-emphasized, Falcon-partial). Each warrants primary-literature verification before promotion.

Two providers of different type were compared: falcon (Edison Scientific, a synthesized pathophysiology report) and asta (a retrieval-only corpus search returning paper snippets, no second-stage synthesis). No direct contradictions were found; divergence is coverage-driven. Falcon uniquely supplies the common genetic risk/protective variant architecture (PNPLA3/TM6SF2/MBOAT7/GCKR/HSD17B13) and the LSEC/nitric-oxide microvascular detail; Asta uniquely surfaces the named etiologic spectrum, the cirrhosis-to-HCC premalignant progression, and a stronger oxidative-stress emphasis. best_matching_text values are verbatim excerpts from the cited report files; per-provider citations are the sources each report leaned on and are not independently verified here.